These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 24633422)

  • 1. Whole-genome sequencing of an aggressive BRAF wild-type papillary thyroid cancer identified EML4-ALK translocation as a therapeutic target.
    Demeure MJ; Aziz M; Rosenberg R; Gurley SD; Bussey KJ; Carpten JD
    World J Surg; 2014 Jun; 38(6):1296-305. PubMed ID: 24633422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.
    Dubey AP; Pathi N; Viswanath S; Rathore A; Pathak A; Sud R
    Indian J Cancer; 2017; 54(1):203-208. PubMed ID: 29199691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation.
    Bae JS; Kim Y; Jeon S; Kim SH; Kim TJ; Lee S; Kim MH; Lim DJ; Lee YS; Jung CK
    Diagn Pathol; 2016 Feb; 11():21. PubMed ID: 26857243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene.
    Isozaki H; Yasugi M; Takigawa N; Hotta K; Ichihara E; Taniguchi A; Toyooka S; Hashida S; Sendo T; Tanimoto M; Kiura K
    Jpn J Clin Oncol; 2014 Oct; 44(10):963-8. PubMed ID: 25170107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
    Kwak EL; Bang YJ; Camidge DR; Shaw AT; Solomon B; Maki RG; Ou SH; Dezube BJ; Jänne PA; Costa DB; Varella-Garcia M; Kim WH; Lynch TJ; Fidias P; Stubbs H; Engelman JA; Sequist LV; Tan W; Gandhi L; Mino-Kenudson M; Wei GC; Shreeve SM; Ratain MJ; Settleman J; Christensen JG; Haber DA; Wilner K; Salgia R; Shapiro GI; Clark JW; Iafrate AJ
    N Engl J Med; 2010 Oct; 363(18):1693-703. PubMed ID: 20979469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-targeted therapy for advanced non-small cell lung cancer: molecular and clinical aspects.
    Okamoto I; Nakagawa K
    Cancer Sci; 2012 Aug; 103(8):1391-6. PubMed ID: 22568572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations of the EGFR, K-ras, EML4-ALK, and BRAF genes in resected pathological stage I lung adenocarcinoma.
    Ohba T; Toyokawa G; Osoegawa A; Hirai F; Yamaguchi M; Taguchi K; Seto T; Takenoyama M; Ichinose Y; Sugio K
    Surg Today; 2016 Sep; 46(9):1091-8. PubMed ID: 26711128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer.
    Ji JH; Oh YL; Hong M; Yun JW; Lee HW; Kim D; Ji Y; Kim DH; Park WY; Shin HT; Kim KM; Ahn MJ; Park K; Sun JM
    PLoS Genet; 2015 Aug; 11(8):e1005467. PubMed ID: 26295973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment.
    Alì G; Proietti A; Pelliccioni S; Niccoli C; Lupi C; Sensi E; Giannini R; Borrelli N; Menghi M; Chella A; Ribechini A; Cappuzzo F; Melfi F; Lucchi M; Mussi A; Fontanini G
    Arch Pathol Lab Med; 2014 Nov; 138(11):1449-58. PubMed ID: 24885803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ALK mutations conferring differential resistance to structurally diverse ALK inhibitors.
    Heuckmann JM; Hölzel M; Sos ML; Heynck S; Balke-Want H; Koker M; Peifer M; Weiss J; Lovly CM; Grütter C; Rauh D; Pao W; Thomas RK
    Clin Cancer Res; 2011 Dec; 17(23):7394-401. PubMed ID: 21948233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
    Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR.
    Wu SG; Kuo YW; Chang YL; Shih JY; Chen YH; Tsai MF; Yu CJ; Yang CH; Yang PC
    J Thorac Oncol; 2012 Jan; 7(1):98-104. PubMed ID: 22124476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.
    Toyokawa G; Seto T
    Respir Investig; 2014 Nov; 52(6):330-8. PubMed ID: 25453376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer.
    Tiseo M; Gelsomino F; Bartolotti M; Bordi P; Bersanelli M; Rossi G; Ardizzoni A
    Expert Rev Anticancer Ther; 2011 Nov; 11(11):1677-87. PubMed ID: 22050016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC.
    Lai Y; Kacal M; Kanony M; Stukan I; Jatta K; Kis L; Norberg E; Vakifahmetoglu-Norberg H; Lewensohn R; Hydbring P; Ekman S
    Biochem Biophys Res Commun; 2019 Apr; 511(2):260-265. PubMed ID: 30791979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytologic, clinicopathologic, and molecular features of papillary thyroid carcinoma with prominent hobnail features: 10 case reports and systematic literature review.
    Lee YS; Kim Y; Jeon S; Bae JS; Jung SL; Jung CK
    Int J Clin Exp Pathol; 2015; 8(7):7988-97. PubMed ID: 26339365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lung adenocarcinoma with concurrent KRAS mutation and ALK rearrangement responding to crizotinib: case report.
    Campos-Gomez S; Lara-Guerra H; Routbort MJ; Lu X; Simon GR
    Int J Biol Markers; 2015 May; 30(2):e254-7. PubMed ID: 25588859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity.
    Kimura H; Nakajima T; Takeuchi K; Soda M; Mano H; Iizasa T; Matsui Y; Yoshino M; Shingyoji M; Itakura M; Itami M; Ikebe D; Yokoi S; Kageyama H; Ohira M; Nakagawara A
    Lung Cancer; 2012 Jan; 75(1):66-72. PubMed ID: 21757253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overcoming the resistance to crizotinib in patients with non-small cell lung cancer harboring EML4/ALK translocation.
    Perez CA; Velez M; Raez LE; Santos ES
    Lung Cancer; 2014 May; 84(2):110-5. PubMed ID: 24598368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.
    Aisner DL; Nguyen TT; Paskulin DD; Le AT; Haney J; Schulte N; Chionh F; Hardingham J; Mariadason J; Tebbutt N; Doebele RC; Weickhardt AJ; Varella-Garcia M
    Mol Cancer Res; 2014 Jan; 12(1):111-8. PubMed ID: 24296758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.